Loading...
•
Sep 30, 2020
Ampio Q3 2020 Earnings Report
Ampio Pharmaceuticals reported a net loss for Q3 2020 and provided updates on its clinical development pipeline.
Key Takeaways
Ampio Pharmaceuticals reported its Q3 2020 financial results, with a net loss of $3.4 million. The company had $9.4 million in cash and cash equivalents as of September 30, 2020. The company provided updates on its COVID-19 platform and OAK clinical trial.
Ampio had $9.4 million in cash and cash equivalents as of September 30, 2020.
Research and development costs were $1.7 million, a 52% decrease compared to the same period in 2019.
Net loss for the third quarter was $3.4 million, compared to a net loss of $7.2 million for the same period in 2019.
The OAK Phase III trial has been paused due to COVID-19, and an SPA amendment was submitted to the FDA.